Lethal injection was meant to be humane. The reality is bloody and brutal.

Experts slam the "completely bogus" treatment while the FDA warns of harmful side effects Vanessa Etienne is a Staff Writer for PEOPLE on the Health team. She joined the brand in 2021. Getty Clinics ...

Add Yahoo as a preferred source to see more of our stories on Google. There were a number of sessions for upcoming T1D and T2D candidates presented at ADA 2026. Credit: Shidlovski / iStock via Getty ...

THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to ...

As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions ...

Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization (4-P MACE) by 21%. The median achieved LDL-C was 45 mg/dL in the Repatha arm ...

VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes VESALIUS-CV is a Phase 3, double-blind, randomized, ...

These days, Nvidia primarily sells AI data center products, and its traditional consumer devices feel like more of a side project. But the company occasionally still releases something designed for ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing proposals in the US. When low-price foreign markets become linked to large U.S ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...